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Abstract: Exacerbations of chronic bronchitis (AECB) are a major cause of morbidity and 
mortality in patients with chronic obstructive pulmonary disease (COPD), and their impact on 
public health is increasing. The new ﬂ  uoroquinolones have an excellent spectrum providing 
cover for the most important respiratory pathogens, including atypical and “typical” pathogens. 
Not surprisingly, different guidelines have inserted these agents among the drugs of choice 
in the empirical therapy of AECB. The pharmacokinetic and dynamic properties of the new 
ﬂ  uoroquinolones have a signiﬁ  cant impact on their clinical and bacteriological efﬁ  cacy. They 
cause a concentration-dependent killing with a sustained post-antibiotic effect. This review 
discusses the most recent data on the new ﬂ  uoroquinolone pruliﬂ  oxacin and critically analyses 
its activity and safety in the management of AECB. 
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Introduction
Chronic bronchitis is estimated to affect between 3.7% and 6.8% of the population 
in Europe (Ball and Make 1998), and prevalence increases with age (McGuire et al 
2001). Patients with chronic bronchitis are predisposed to recurrent attacks of bronchial 
inﬂ  ammation—termed acute exacerbations of chronic bronchitis (AECB)—character-
ized by increased cough, worsening dyspnea, and changes in sputum purulence and 
volume (Anthonisen et al 1987). Infectious agents are estimated to account for around 
80% of these episodes, with the remaining 20% attributed to noninfectious causes such 
as inadequate medical treatment, congestive heart failure, pulmonary embolism, etc 
(Sethi 2000). Patients with recurrent exacerbations are exposed to frequent courses of 
antimicrobials with a possible selection of antimicrobial resistance among common 
bacterial pathogens. Antibacterial therapy for AECB is aimed at relieving symptoms, 
preventing loss of pulmonary function that may lead to hospitalization, speeding 
recovery, and prolonging the time to the next exacerbation. 
Fluoroquinolones are widely used antibiotics for the treatment of AECB due to 
their excellent pharmacokinetic/dynamic properties, high antimicrobial activity, and 
low incidence of side-effects (Blasi et al 2003).
We will review the available data on pruliﬂ  oxacin efﬁ  cacy and tolerability in the 
treatment of AECB.The review is based on a PUBMED literature search, using as key-
word “pruliﬂ  oxacin”, for original articles and reviews published in English from Janu-
ary 1990 to April 2006. Thirty-ﬁ  ve articles were retrieved, 15 articles on urinary tract 
infections or strictly preclinical studies were discarded, and 20 papers were analysed.
Pharmacokinetic and pharmacodynamic features
Pruliﬂ  oxacin (6-ﬂ  uoro-1-methyl-7-[4-[(5-methyl-2-oxo-1, 3-dioxol-4-yl)methyl]-1-
piperazinyl]-4-oxo-1H, 4H-[1, 3]thiazeto[3, 2-a]quinoline-3-carboxylic acid), the prodrug International Journal of COPD 2007:2(1) 28
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of ulifloxacin, is a broad-spectrum oral fluoroquinolone 
antibacterial agent. After absorption, prulifloxacin is 
metabolized by esterases to uliﬂ  oxacin. Pruliﬂ  oxacin is absorbed 
mainly from the upper small intestine and then metabolized to 
uliﬂ  oxacin in the liver by an α-esterase (paraoxonase) (ﬁ  rst pass 
or presystemic metabolism) (Tougou et al 1998). 
Table 1 shows pharmacokinetic characteristics of 
pruliﬂ  oxacin (Picollo et al 2003; Matera 2006).Uliﬂ  oxa-
cin concentrations in serum and lung have been recently 
evaluated (Concia et al 2005). In this open label study 27 
patients with lung carcinoma requiring surgical intervention 
were recruited. A single dose of pruliﬂ  oxacin 600 mg was 
administered and concentrations evaluated at 2, 4, 6, 12, or 
24 hours preoperatively. Uliﬂ  oxacin concentrations in plasma 
and lung tissue were determined by reversed-phase high-
performance liquid chromatography. The results reported 
show lung tissue levels higher than plasma levels, however 
values appear to be widely dispersed. At time 2, 4, 6, 12, and 
24-hour the values ranges (lung tissue after correction for 
blood contamination) were 1.02–5.98, 1.39–4.59, 0.33–5.27, 
0.46–3.63, and 0.28–3.0, respectively. The mean lung/plasma 
concentration ratio was 6.9 ± 0.6 (standard error) reﬂ  ecting 
the wide dispersion of concentration values. 
Good intracellular penetration in macrophages and human 
polimorphonuclear cells has been reported (Ozaki et al 1996). 
Uliﬂ  oxacin strengthens the phagocytic and microbicidal 
activities of the peritoneal macrophages against Klebsiella 
pneumoniae (Tullio et al 2000). When intracellularly concen-
trated, uliﬂ  oxacin can kill the bacteria directly or make them 
more susceptible to the phagocyte bactericidal effect (Tullio 
et al 1999). Moreover, uliﬂ  oxacin seems to modulate human 
polymorphonuclear (PMN)’s in vitro synthesis of proinﬂ  am-
matory cytokines such as interleukin (IL)-8, IL 1β, and tumor 
necrosis factor-α (TNFα) (Reato et al 2004).
Drug interactions
In healthy volunteers co-administration of theophylline 
and pruliﬂ  oxacin induces an increase of 15% theophylline 
area under the curve (AUC) and T½ and a 15% reduction of 
clearance (Fattore et al 1998). Likewise the other ﬂ  uoroqui-
nolones, cation-containing antacid, and iron preparations 
reduce absorption of pruliﬂ  oxacin, these drugs should be 
administered 3 hours before or 2 hours after pruliﬂ  oxacin 
(Keam et al 2004; Prats et al 2006).
Microbiology
Uliﬂ  oxacin, the active metabolite of pruliﬂ  oxacin, shows 
a wide spectrum of activity against Gram-positive and 
Gram-negative bacteria. In this review we will address the 
activity against the main respiratory pathogen involved in 
exacerbations of chronic bronchitis. As stated in a recent 
paper by Roveta and colleagues (2005), due to the absence of 
a deﬁ  ned breakpoint for pruliﬂ  oxacin/uliﬂ  oxacin all the data 
are referred to ciproﬂ  oxacin breakpoint. This clearly hampers 
the clinical interpretation of the susceptibility data.
The activity against Streptococcus pneumoniae seems to 
vary considerably between studies. In three of these studies 
the uliﬂ  oxacin activity against S. pneumoniae resulted in 
fairly low minimum inhibitory concentration (MIC) values 
ranging from 0.12 to >4 μg/ml, with a MIC required to 
inhibit the growth of 90% of organisms (MIC90) value of 
>4 μg/ml (Ozaki et al 1991; Yoshida and Mitsuhashi 1993; 
Prats et al 2002). 
In their study, Prats and colleagues showed a MIC50 
of uliﬂ  oxacin of 1 μg/ml against the penicillin-susceptible 
strains and 2 μg/ml for those presenting moderate and high 
resistance; the MIC90 was 4 μg/ml for the penicillin-sensitive 
and intermediate strains and 2 μg/ml for the highly resistant 
strains (Prats et al 2002).
Another study, performed on 36 Italian strains, showed a 
better activity with MIC values ranging from 0.015 to 2 μg/ml 
and a MIC90 value of 1 μg/ml (Montanari et al 2001).
Uliﬂ  oxacin in vitro activity against strains of methicil-
lin-susceptible Staphylococcus aureus is fairly good with a 
reported MIC90 value of <0.5 μg/ml (Montanari et al 2001; 
Prats et al 2002). No activity was demonstrated against 
methicillin-resistant strains.
The spectrum of activity mainly addresses Gram negative 
bacteria, including Pseudomonas aeruginosa. 
Roveta and colleagues (2005) performed a susceptibility 
study on 300 clinical isolates. Using ciproﬂ  oxacin breakpoint, 
72% of the strains were susceptible and pruliﬂ  oxacin resulted 
in the most powerful available antipseudomonal ﬂ  uoroqui-
nolone with MIC values ranging from 0.015 to 128 μg/ml 
and a MIC90 of 16 μg/ml.
Table 1 Pharmacokinetic characteristics of pruliﬂ  oxacin (active 
metabolite uliﬂ  oxacin)
Dose  T max  C max  Protein  T½ (h)  AUC∞   Clearance
(mg) (h)  (mg  L–1) binding     (μg⋅h/ml)  (ml⋅min−1⋅kg)
     (%)
600   1  2  41–59  10  8  170
Abbreviations: AUC∞, area under the plasma concentration time curve from 
time 0 to inﬁ  nity; Cmax, maximal concentration; Tmax, time to reach maximal concen-
tration; T½, half-life.International Journal of COPD 2007:2(1) 29
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In this study time–kill tests at 4× MIC conﬁ  rmed the 
pronounced bactericidal potency of the drug against P. 
aeruginosa. Amongst the members of the ﬂ  uoroquinolone 
class assessed, pruliﬂ  oxacin produced the lowest mutant 
prevention concentration (MPC) values (4 μg/ml).
Uliﬂ  oxacin activity against Enterobacteriaceae is one of 
the best among ﬂ  uoroquinolones, with MIC90 values ranging 
from 0.015 to 0.25 μg/ml .
Haemophilus inﬂ  uenzae and Moraxella catarrhalis are 
both highly susceptible to uliﬂ  oxacin with a MIC90 always 
lower than 0.12 μg/ml.
No data are reported in the literature on the activity against 
Mycoplasma pneumoniae and Chlamydophila pneumoniae, 
though Keam and Perry (2004) report unpublished data on a 
limited activity of uliﬂ  oxacin against C. pneumoniae. 
Clinical study
One study has been published on the activity of pruliﬂ  oxacin 
in AECB indication (Grassi et al 2002). This double-blind, 
double-dummy, randomized study compared pruliﬂ  oxacin 
600 mg once daily with ciproﬂ  oxacin 500 mg twice daily 
for 10 days. The study was performed in 18 French and 7 
Italian centers. A total of 235 patients (117 pruliﬂ  oxacin and 
118 ciproﬂ  oxacin) with Anthonisen I and II exacerbations of 
chronic bronchitis were enrolled (Anthonisen et al 1987). The 
clinical response at the end of treatment was assessed as: (i) 
cure (resolution of all baseline symptoms), (ii) improvement 
(decrease in intensity of all symptoms), and (iii) failure (no 
decrease in the intensity of at least one symptom detected 
at baseline). The primary parameter for the evaluation of 
efﬁ  cacy was the clinical outcome. Clinical cure or improve-
ment were considered as therapeutic success. 
Ninety-four patients (50 in pruliﬂ  oxacin and 44 in cipro-
ﬂ  oxacin group) had a microbiological evaluation on sputum 
culture. The bacteriologic response was based on the result 
of the sputum culture at the end of treatment as compared 
with baseline and was assessed as follows: (i) eradication (the 
pathogen observed at baseline was not found at endpoint); (ii) 
presumed eradication (absence of sputum sample because the 
patient was clinically improved); (iii) persistence (presence of 
causative organism at the end of therapy); (iv) superinfection 
(a new organism at the end of therapy, regardless of whether 
the original pathogen was present). Eradication and presumed 
eradication were considered a microbiological success.
Two hundred and twenty-one patients (94%) completed 
the study. Table 2 shows clinical and microbiological results. 
One or more drug-related adverse events were reported by 
15.4% (18/117) and 12.7% (15/118) patients in pruliﬂ  oxacin 
and ciproﬂ  oxacin group, respectively. The most common 
treatment-related adverse event in both treatment groups 
was gastric pain, reported by 10/117 (8.5%) and 8/118 
(6.8%) patients in pruliﬂ  oxacin and ciproﬂ  oxacin group, 
respectively.
One unpublished study comparing pruliﬂ  oxacin with 
amoxicillin-clavulanate is reported in three reviews (Keam 
and Perry 2004; Cazzola et al 2006; Prats et al 2006), 
and another unpublished dose-ﬁ  nding study by Cazzola 
and colleagues (Cazzola et al 2006). 
These two studies will not be described in the present 
review as they are not published. 
Safety and tolerability
Limited data are reported in the literature on tolerability of 
pruliﬂ  oxacin in the treatment of respiratory infections. In the 
Grassi and colleagues (2002) study the pattern and incidence 
(around 10%–15%) of adverse reaction were similar in 
pruliﬂ  oxacin and ciproﬂ  oxacin treated patients, and mainly 
related to gastrointestinal disturbances. In their review, Prats 
and colleagues (2006) report on some data on ﬁ  le concerning 
phototoxicity. They describe a cross-over study on healthy 
volunteers that showed comparable effects with that of cip-
roﬂ  oxacin. Two studies address the potential cardiotoxicity 
of pruliﬂ  oxacin (Lacroix et al 2003; Akita et al 2004). Both 
Table 2 Clinical and microbiological results in patients with 
exacerbations of chronic bronchitis treated with pruliﬂ  oxacin 
600 mg once daily or ciproﬂ  oxacin 500 mg twice daily for 10 
days (modiﬁ  ed from Grassi et al 2002)
 Pruliﬂ  oxacin  Ciproﬂ  oxacin
  (110 patients)  (111 patients)
Clinical outcomes
(MITT population)   
Cure 15.3%  11.5%
Improvement 69.4%  73.5%
Failure 15.3%  15.0%
Microbiological outcomes
(94 patients, 50 pruliﬂ  oxacin
and 44 ciproﬂ  oxacin)  
Eradication/Presumed
eradication (overall)  88.7%  92%
Main pathogens:
Haemophilus inﬂ  uenzae 17/19    15/15
Streptococcus pneumoniae 8/9  9/12
Klebsiella pneumoniae 5/5  8/8
Pseudomonas aeruginosa 4/5    3/4
Staphylococcus aureus 5/5  2/2International Journal of COPD 2007:2(1) 30
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these studies show negligible effects on cardiac depolariza-
tion/repolarization cycle in vitro and in vivo indicating a very 
low probability of Qc interval prolongation.
Positioning of pruliﬂ  oxacin 
in the treatment of AECB
Isolation of bacteria from sputum samples and the distal 
airways using a protected specimen brush (Fagon et al 1990; 
Soler et al 1998) has identiﬁ  ed Haemophilus inﬂ  uenzae, 
Streptococcus pneumoniae, and Moraxella catarrhalis as 
the predominant respiratory pathogens in patients with 
AECB, with H.inﬂ  uenzae being identiﬁ  ed most frequently (in 
30%–70% of all episodes) . Other bacteria identiﬁ  ed in bron-
chial samples include the atypical pathogens Chlamydophila 
(Chlamydia) pneumoniae and Mycoplasma pneumoniae, 
which have been implicated either as the sole causative 
agent or as co-pathogens in approximately 5%–15% of acute 
exacerbations (Blasi et al 1993; Mogulkoc et al 1999). The 
nature of the causative pathogen tends to vary according 
to the severity of the underlying chronic bronchitis and the 
degree of lung function impairment. 
Ofﬁ  cial or unofﬁ  cial guidelines for the classiﬁ  cation and 
antibacterial treatment of AECB and/or exacerbations of 
COPD are available in a number of countries.
The treatment choice usually depends on a number of 
factors, including suspected or conﬁ  rmed aetiology, clini-
cal features and history, and local patterns of antibacterial 
resistance. Other relevant factors include the tolerability, 
convenience, and cost of treatment. Two additional criteria 
for antibacterial selection should be taken into account, the 
ability of the antibacterial to penetrate bronchial tissue and 
mucus, and low ecological risk (ie, a low propensity to in-
duce resistance). Across the guidelines, patients with chronic 
bronchitis or COPD presenting with symptoms of an acute 
exacerbation are usually stratiﬁ  ed into three groups. The ﬁ  rst 
group of patients presents with 2 Anthonisen criteria, but 
generally have only mild to moderate impairment of lung 
function (forced expiratory volume in one second [FEV1] 
>50% of the predicted value), no comorbidities and <3 ex-
acerbations/year. A second group of patients is characterized 
by the presence of additional risk factors for treatment failure, 
which include moderate to severe lung function impairment 
(FEV1 >35%–<50% of the predicted value) and/or signiﬁ  cant 
comorbidity (eg, cardiac disease, diabetes, hepatic/renal 
insufﬁ  ciency) and/or frequent exacerbations (4/year). Pa-
tients considered at the highest risk for treatment failure are 
included in the third group and often demonstrate very severe 
impairment of lung function (FEV1
 <35% of the predicted 
value) and/or multiple risk factors (including signiﬁ  cant 
comorbidity, chronic corticosteroid therapy) and frequent 
exacerbations (≥4/year). 
This kind of patient stratiﬁ  cation is also related to the 
bacterial ﬂ  ora associated with the exacerbations. 
Thus, in patients with mild to moderate chronic bronchi-
tis, H. inﬂ  uenzae and S. pneumoniae are the most commonly 
isolated bacteria during AECB, while Staphylococcus aureus 
and Gram-negative bacteria, including Pseudomonas aeru-
ginosa and Enterobacteriaceae species, are predominantly 
isolated from patients with a severe degree of airﬂ  ow obstruc-
tion (FEV1 <35% of the predicted value) (Eller et al 1998; 
Miravitlles et al 1999).
Notwithstanding the paucity of published clinical data, 
the antimicrobial spectrum and the results of Grassi and col-
leagues (2002) study seem to indicate the possible role of 
pruliﬂ  oxacin in the treatment of exacerbations of outpatients 
with moderate to severe COPD, which are generally caused 
by Gram-negative bacteria (mainly Haemophilus inﬂ  uenzae), 
Enterobacteriaceae, and Pseudomonas spp.
Conclusions
Pruliﬂ  oxacin is a new ﬂ  uoroquinolone with indications in 
the treatment of urinary tract infection and acute exacerba-
tions of chronic bronchitis. The antibacterial spectrum is 
similar to that of ciproﬂ  oxacin with clear advantages in 
terms of antipseudomonal in vitro activity. Only few data 
on pharmacokinetic and pharmacodynamic characteristics, 
including bronchial and lung tissues, have been published. 
The available data indicate a fairly good penetration into the 
lung tissue with high intracellular concentrations in phago-
cytes and PMNs, with an interesting “immunomodulatory” 
activity. The only published AECB treatment study shows 
a clinical and microbiological activity comparable with 
ciproﬂ  oxacin. 
More data are clearly required to better evaluate the role 
of this new ﬂ  uoroquinolone in the panorama of antibiotics.
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